ライフサイエンスコーパス: vaginal

1 nfection probability via penile (10-1074) or vaginal (10-1074 or 3BNC117) challenge routes.

2 use of vaginal discharge and associated with vaginal acquisition of BV-associated bacteria (BVAB).

3 Vaginal administration of the TDF-FTC-VRC01-N combinatio

4 osae, for example CCL25 enhanced splenic and vaginal Ag-specific T cell responses whereas CCL28 incre

5 examination including collection of cervical/vaginal and anal specimens, followed by high-resolution

6 Therefore, the vaginal and anorectal mucosa are relevant sites for ZIKV

7 a decreased ability to associate with human vaginal and cervical cells in vitro but did not contribu

8 Baseline vaginal and extra-vaginal colonization with Gardnerella

9 recruitment of B and T cells to the spleen, vaginal and intestinal mucosae, for example CCL25 enhanc

10 tant commensal and beneficial microbe in the vaginal and intestinal tracts.

11 We determined how the vaginal and penile microbiomes contribute to HSV-2 seros

12 We modeled vaginal and penile taxa and covariates contributing to H

13 The D(IP-10) P(ALFQ) regimen also increased vaginal and rectal IgA antibodies to a greater extent.

14 ding the sexual transmission of ZIKV through vaginal and rectal routes is necessary to restrict virus

15 geted surgical procedures: cesarean section, vaginal, and abdominal hysterectomy, colon, laminectomy,

16 fferences in microbial communities influence vaginal antibiotic efficacy.

17 These data suggest that the vaginal antimicrobial response induced by flagellin acti

18 We recently showed that vaginal application of aminoglycoside antibiotics induce

19 irculation to the genital mucosa via topical vaginal application of chemokines in mice.

20 inal products on uropathogenic and commensal vaginal bacteria is poorly understood.

21 at mutually beneficial relationships between vaginal bacteria support pathogen colonization and may h

22 Using human vaginal bacterial communities, we show that F. nucleatum

23 improved vaginal progesterone absorption and vaginal biocompatibility could be more effective for PTB

24 ompared with planned TOLAC anned PCS (PPCS), vaginal birth after 1 previous CS (VBAC-1) and associate

25 alth goal; despite evidence of the safety of vaginal birth after cesarean delivery, most women have s

26 no statistically significant differences in vaginal birth rates (31.8% in both groups; adjusted abso

27 The primary outcome was trial of labor; vaginal birth was the main secondary outcome.

28 of obstetric anal sphincter injury following vaginal birth were found in countries with higher rates

29 ed by the maternal H. pylori status, only in vaginal birth, not in C-section delivery.

30 ; mean birth weight, 1985 g [SD, 958 g]; 76% vaginal birth; mean parent age, 31 [SD, 7] years), of wh

31 rho = -0.62) and higher rates of spontaneous vaginal births (multiparous: rho = 0.70).

32 al (rho = 0.67) and spontaneous (rho = 0.66) vaginal births among multiparous women and lower rates o

33 42% to 70% versus 50% to 84% for spontaneous vaginal births.

34 6% to 68% versus 2% to 30% for episiotomy in vaginal births; 3% to 30% versus 1% to 7% for instrument

35 ; 3% to 30% versus 1% to 7% for instrumental vaginal births; and 42% to 70% versus 50% to 84% for spo

36 iple logistic regression which also included vaginal bleeding as a predictor.

37 ks (31.2%) and those with a short cervix and vaginal bleeding in the first half of pregnancy (40%).

38 ed cesarean section at 39 weeks or attempted vaginal breech delivery.

39 cans carriers, and symptomatic patients with vaginal candidiasis were enrolled in this study.

40 pseudohyphae/hyphae is required to determine vaginal candidiasis; however, it may be not sufficient t

41 nt use of oral metronidazole, Ecologic Femi+ vaginal capsule (containing multiple Lactobacillus and o

42 al colonization model to explore E. faecalis vaginal carriage and demonstrate that both vancomycin-re

43 onization model, E. coli are detected inside vaginal cells and the urinary tract, indicating that vag

44 e critically, bacteria are identified inside vaginal cells from clinical samples from women with a hi

45 isolates not only adhere to, but also invade vaginal cells.

46 nal colonization, we observed E. faecalis in vaginal, cervical, and uterine tissue.

47 Vaginal challenges of wild-type (WT), Y181C, and Y181V H

48 After ten vaginal challenges with autologous virus, protection was

49 of clinical isolates and hastens gonococcal vaginal clearance in mice.

50 how HepI glycan extensions affect (i) mouse vaginal colonization and (ii) efficacy in vitro and in v

51 As estrogen increases susceptibility to vaginal colonization and resulting immunopathology, we a

52 ut specific factors that promote E. faecalis vaginal colonization and subsequent infection.

53 These results reveal the complex nature of vaginal colonization and suggest that multiple factors c

54 83 mutants that were underrepresented during vaginal colonization at 1, 5, and 8 days postinoculation

55 cells and the urinary tract, indicating that vaginal colonization can seed the bladder.

56 male reproductive tract, and reports suggest vaginal colonization increases following antibiotic trea

57 We modified an established mouse vaginal colonization model to explore E. faecalis vagina

58 Conversely, in a vaginal colonization model, E. coli are detected inside

59 Baseline vaginal and extra-vaginal colonization with Gardnerella spp., Megasphaera

60 Following vaginal colonization, we observed E. faecalis in vaginal

61 system were attenuated in persisting during vaginal colonization.

62 able to consume sialic acids was impaired in vaginal colonization.

63 Vaginal community dominance by Lactobacillus crispatus o

64 on was independently associated with diverse vaginal community state type (CST)-IVA (P = .005) and CS

65 Vaginal, compared with cesarean delivery, was most stron

66 s determined by number of mice with positive vaginal cultures, number of positive cultures, number of

67 HPV and HIV acquisition and relate these to vaginal cytokine profiles in an observational cohort of

68 eliveries (SVD) and 3 days post instrumental vaginal deliveries (IVD).

69 iotomy rates fell from 21.6 to 14.3% for all vaginal deliveries (p < 0.01), and from 15.5 to 9.3% (p

70 marks following VD: 2 days after spontaneous vaginal deliveries (SVD) and 3 days post instrumental va

71 ) on healthy mothers and term newborns after vaginal deliveries (VD) is still inconclusive and little

72 There were 4 vaginal deliveries and 2 cesarians.

73 s according to whether a woman has any prior vaginal deliveries and the number of prior cesarean sect

74 e population-based cohort study, we included vaginal deliveries performed in French hospitals (N = 58

75 Among non-operative vaginal deliveries, epidural analgesia, non-reassuring f

76 5.5 to 9.3% (p < 0.01) for all non-operative vaginal deliveries.

77 f episiotomy, particularly for non-operative vaginal deliveries.

78 f complications such as preeclampsia and non-vaginal deliveries.

79 ors associated with its use in non-operative vaginal deliveries.

80 onsmoker, had undergone uncomplicated normal vaginal delivery 15 years earlier, was not taking oral c

81 Of these, 181 mothers had a vaginal delivery and 143 had a CS delivery (60 with and

82 ory activities, showed a twofold increase in vaginal delivery compared to CS with or without labor (a

83 microbial peptides (AMP) were upregulated in vaginal delivery compared to CS with or without labor.

84 nce of antimicrobial peptide upregulation in vaginal delivery compared to CS with or without labor.

85 y and significantly lower in infants born by vaginal delivery compared with those born by elective ce

86 p = 0.019) with injury relative to uninjured vaginal delivery controls at 3d.

87 across calendar years was marginal for both vaginal delivery modes (VDM).

88 Vaginal delivery with obstetrical trauma is a risk facto

89 evels of S100A8-A9 than from infants born by vaginal delivery.

90 e was delivered at full term via spontaneous vaginal delivery.

91 pregnant baboons (n = 6) were inoculated via vaginal deposition of baboon semen containing 10(6) focu

92 nhuman primates to demonstrate infection via vaginal deposition of Zika virus-infected semen.

93 We hypothesized that vaginal deposition of ZIKV-infected baboon semen would l

94 acterial vaginosis (BV) is a common cause of vaginal discharge and associated with vaginal acquisitio

95 protected mice from HSV-1 and HSV-2 skin or vaginal disease and prevented latency following active o

96 iate bacterial vaginosis from other types of vaginal disorders, but none predict recurrence after tre

97 possible mechanism underlying links between vaginal dysbiosis and oral sex.

98 Depot medroxyprogesterone acetate (DMPA) and vaginal dysbiosis have been implicated in increased risk

99 isms supporting pathogen colonization during vaginal dysbiosis remain obscure.

100 permissive environment for pathogens during vaginal dysbiosis.

101 suggests that COC use may induce an optimal vaginal ecosystem by decreasing bacterial diversity and

102 Immortalised vaginal epithelial cells (VK2 E6/E7), modelling the vagi

103 d products alone and in the presence of both vaginal epithelial cells and selected products.

104 ture of selected products in the presence of vaginal epithelial cells eliminated the inhibitory effec

105 Cytokine production by vaginal epithelial cells in response to lactobacilli in

106 nary tract infections (UTIs) - can adhere to vaginal epithelial cells preceding UTI.

107 thermore, no aBL-induced genotoxicity to the vaginal epithelial cells was observed at the radiant exp

108 Adhesion to vaginal epithelial cells, pH, D/L-lactate production and

109 inhibition was mitigated by the presence of vaginal epithelial cells.

110 e effects of a topical estrogen treatment on vaginal epithelial responses following challenge with E.

111 facilitates transmigration of DCs across the vaginal epithelium in the mouse female reproductive trac

112 Intracellular colonization of the vaginal epithelium is detected in acute and chronic muri

113 epithelial cells (VK2 E6/E7), modelling the vaginal epithelium were treated with either 4 nM 17beta-

114 ught to characterize the interaction between vaginal epithelium, G. vaginalis, and VLY using EpiVagin

115 upport gammadelta T cells located within the vaginal epithelium.

116 is normally colonizes the apical face of the vaginal epithelium.

117 Clinically, topical vaginal estrogen treatment has a prophylactic effect aga

118 cy and parturition have a profound impact on vaginal FBLN5 and biomechanics of the vaginal wall.

119 Vaginal FBLN5 decreased significantly in pregnancy, and

120 ntial risk factors to estimate the burden of vaginal fistula among women of childbearing age.

121 childbearing age with lifetime and untreated vaginal fistula in 2016 were 72,533 (95% CI 38,235-124,1

122 s substantial reduction in the prevalence of vaginal fistula in Ethiopia.

123 Vaginal fistula is a shattering maternal complication ch

124 icant subnational variation in the burden of vaginal fistula.

125 and implementation of interventions against vaginal fistula.

126 4 (95% CI 26,580-118,158) untreated cases of vaginal fistula.

127 d sustained concentrations of 5P12-RANTES in vaginal fluid and vaginal tissue between 10 and 10,000 n

128 Vaginal fluid samples were collected shortly after amnio

129 concentrations were quantified in plasma and vaginal fluid.

130 ion VRs both achieved peak concentrations in vaginal fluids, which were substantially higher compared

131 ymmetry resulted from complex 3D spirals and vaginal folds with deep recesses, which may curtail the

132 for sociodemographics and BV, enrichment of vaginal Gardnerella vaginalis and Lactobacillus iners wa

133 and high diversity profiles, associated with vaginal health outcomes, prevail in these populations.

134 inflammatory cytokine IL-17A to regulate the vaginal host defences during infection.

135 uterovaginal pelvic organ prolapse following vaginal hysterectomy.

136 Origins of vaginal IL-17 in vivo remain unclear, but patient biopsi

137 ion which might contribute to an exaggerated vaginal immune response to Candida hyphae.

138 sure to prevent dissemination of HIV-1 after vaginal infection and low-frequency resistance mutations

139 acy against Neisseria gonorrhoeae in a mouse vaginal infection model.

140 In 394 vaginal infections, cure was 93.5% (95% CI, 90.1%-96.1%;

141 ileged eye, however, may differ from skin or vaginal infections.

142 nfection that resembles human disease, using vaginal inoculation combined with mild cervical injury i

143 at sexual debut and history of heterosexual vaginal intercourse.

144 indings suggest that E. coli can establish a vaginal intracellular reservoir, where it may reside saf

145 Endotoxin concentrations in vaginal lavage fluid from SPI dams were significantly hi

146 pression from murine reproductive tracts and vaginal lavages collected 24 and 72 h post-administratio

147 ivered preterm exhibited significantly lower vaginal levels of Lactobacillus crispatus and higher lev

148 geometric morphometrics and 3D models of the vaginal lumen and inflated distal penis.

149 The asymmetric shapes of the vaginal lumen and penis tip were both left-canted with s

150 nclusion, metabolic changes in the NMR-based vaginal metabolic profile are able to discriminate the p

151 Vaginal metabolites are influenced by resident vaginal m

152 dational data documenting differences in the vaginal metabolome between CT+, CT+/MG+ and uninfected w

153 Here, we aimed to evaluate whether the vaginal metabolome discriminates the presence/absence of

154 n is understudied and the composition of the vaginal metabolome in CT/MG co-infected women is unknown

155 Examining the vaginal metabolome in the context of CT mono (CT+) and C

156 Yet, the vaginal metabolome in the setting of CT infection is und

157 ound that CT+ and CT+/MG+ women had distinct vaginal metabolomic profiles as compared to uninfected w

158 The vaginal metabolomics profile of MIAC showed higher conce

159 y characterize the structure and function of vaginal metagenome and metatranscriptome datasets.

160 tility of VIRGO, we analyze 1,507 additional vaginal metagenomes, and identify a high degree of intra

161 vaginosis and who had completed a course of vaginal metronidazole gel as part of the eligibility req

162 The use of Lactin-V after treatment with vaginal metronidazole resulted in a significantly lower

163 We compared vaginal microbial communities in postmenopausal Black an

164 We identified small overall differences in vaginal microbial communities of Black and White postmen

165 Vaginal microbial communities of pregnant women with HIV

166 A high diversity vaginal microbial community with paucity of Lactobacillu

167 y endpoints were cervical T cell activation, vaginal microbial diversity and cytokine concentrations.

168 Adolescents randomized to COCs had lower vaginal microbial diversity and relative abundance of HI

169 ated evidence for a relationship between the vaginal microbiome and reproductive performance, suggest

170 iation was found between urban level and the vaginal microbiome in Amerindian women, and little diffe

171 In this study, we compared the vaginal microbiome in sows with low and high farrowing p

172 We examined the vaginal microbiome in two cohorts of women who experienc

173 we analyzed an interesting data set from 396 vaginal microbiome samples where the ground truth for th

174 acterial vaginosis (BV), an imbalance of the vaginal microbiome, are more likely to be colonized by p

175 ed in women with non-Lactobacillus-dominated vaginal microbiomes.

176 g evidence suggests associations between the vaginal microbiota (VMB) composition, human papillomavir

177 he complex interplay between host, virus and vaginal microbiota (VMB).

178 In this study, we characterize the vaginal microbiota and immune factors in pregnant Africa

179 though HIV is associated with alterations in vaginal microbiota and inflammation in nonpregnant women

180 gene amplicon sequencing to characterize the vaginal microbiota and metabolomes of CT+, CT+/MG+, and

181 We examined the relationship between the vaginal microbiota and persistent hrHPV infection in HIV

182 e) and evaluated the association between the vaginal microbiota and persistent hrHPV infection using

183 The relationship between the vaginal microbiota and persistent hrHPV was modified by

184 Vaginal microbiota assessments at all visits included Gr

185 allenges, and Nubeam detected differences in vaginal microbiota between cases of polycystic ovary syn

186 In conclusion, this study demonstrates that vaginal microbiota collected after PRRS vaccination coul

187 n microscopic findings of Pap smears and the vaginal microbiota composition determined by next genera

188 at the impact of antibiotic treatment on the vaginal microbiota could favor reinfections.

189 terized the composition and structure of the vaginal microbiota in a cohort of 149 women with genital

190 o test this hypothesis, we characterized the vaginal microbiota in the cervicovaginal and introital s

191 During pregnancy, the vaginal microbiota is relatively stable.

192 The vaginal microbiota is thought to play a role in modulati

193 and reproductive performance, suggesting the vaginal microbiota may serve as a tool to predict farrow

194 The vaginal microbiota of healthy women typically has low di

195 used 16S-rRNA sequencing to characterize the vaginal microbiota of two serial samples taken six month

196 However, African women have more diverse vaginal microbiota than their European counterparts, in

197 zed by a shift from a Lactobacillus-dominant vaginal microbiota to a polymicrobial microbiota, consis

198 es, and were less likely to have a dysbiotic vaginal microbiota type by sequencing.

199 At time of diagnosis, the vaginal microbiota was dominated by Lactobacillus iners

200 ginal metabolites are influenced by resident vaginal microbiota, affect susceptibility to sexually tr

201 ing effect(s) of antibiotic treatment on the vaginal microbiota, and to develop strategies to protect

202 of intraspecies diversity within and across vaginal microbiota.

203 men both before and after adjustment for the vaginal microbiota.

204 also associated with Lactobacillus-deficient vaginal microbiota.

205 op strategies to protect and restore optimal vaginal microbiota.

206 In mice with sialidase-producing vaginal microbiotas, mutant F. nucleatum unable to consu

207 However, as time goes by, the artificial vaginal microecological condition gradually becomes norm

208 a more in-depth understanding of the role of vaginal microorganisms in women's health and reproductiv

209 In conclusion, in vitro exposure to vaginal moisturizing and lubricating products inhibited

210 ic, is sufficient to pull CD8 T cells to the vaginal mucosa and provide protection against genital he

211 nes required for colonization of the primate vaginal mucosa in vivo and 96 genes required for infecti

212 e modalities and to topical drug delivery to vaginal mucosa more generally.

213 d the levels of specific T cells only in the vaginal mucosa.

214 the intestinal tract, on the skin or on the vaginal mucosa.

215 B cells to home to the gastrointestinal and vaginal mucosae using genetic chemokine adjuvants and as

216 his study, we assemble a comprehensive human vaginal non-redundant gene catalog (VIRGO) that includes

217 Mode of birth was categorised as vaginal or CS (emergency/elective).

218 bo tablet, both followed by a single dose of vaginal, oral, or sublingual misoprostol 800 mug 2 days

219 We also construct a vaginal orthologous groups (VOG) from VIRGO.

220 ith Chlamydia confers protection against per-vaginal (p.v.) challenge, resulting in significantly dec

221 s results were concordant between the BD MAX Vaginal Panel and the BD MAX CT/GC/TV assay in 559 of 56

222 Secondary endpoints of vaginal, pelvic, and distant recurrence were analysed ac

223 The performance of vaginal pH testing for bacterial vaginosis improved by i

224 ntial for the generation of a protective low vaginal pH, in the cervicovaginal microbiota.

225 e biosensors capable of monitoring sweat and vaginal pH.

226 Vaginal plate opening (VPO) occurs in response to the ma

227 Vaginal plate opening and ovipositor extrusion are thus

228 Virgin females are more likely to open their vaginal plates in response to song; mated females are mo

229 ther of two discrete actions: opening of the vaginal plates to allow copulation, or extrusion of the

230 gnals her willingness to mate by opening her vaginal plates, allowing a courting male to copulate(1,2

231 Lactobacilli-based vaginal probiotics warrant further evaluation because, i

232 axis (PrEP) and form a promising basis for a vaginal product.

233 We evaluated the effect of five common vaginal products (KY Jelly, Replens Silky Smooth lubrica

234 The effect of vaginal products on uropathogenic and commensal vaginal

235 ighly effective, female-controlled, discrete vaginal products therefore is needed to help curb the ep

236 of menopause, for which many use lubricating vaginal products.

237 ne formulation that is designed for improved vaginal progesterone absorption and vaginal biocompatibi

238 Vaginal progesterone supplementation has been demonstrat

239 nd aurothioglucose did not inhibit growth of vaginal protective commensal lactobacilli.

240 e-specific IgG responses in serum as well as vaginal, rectal and salivary secretions.

241 A total of 510 vaginal-rectal prepartum specimens were tested simultane

242 rol/ethinyl estradiol combined contraceptive vaginal ring (CCVR) for 16 weeks, then crossed over to a

243 eptability of a microbicide dapivirine (DPV) vaginal ring (VR) versus placebo in postmenopausal women

244 oenanthate (NET-EN), combined contraceptive vaginal rings (CCVR; NuvaRing), and combined oral contra

245 Vaginal rings (VR) containing antiretroviral (ARV) drugs

246 Vaginal rings (VRs) are a promising approach for sustain

247 Maternal vaginal samples and infant oral cavity and stool samples

248 erial DNA sequencing from serially collected vaginal samples from a cohort of 87 adolescent and young

249 Vaginal samples were collected at baseline and every 6 m

250 Vaginal secretions of p.o.-immunized animals neutralize

251 unvaccinated girls (1993-1994) who provide a vaginal self-swab sample, serum sample, and questionnair

252 aged by vaginoscopic incision of the oblique vaginal septum using a "No-touch" technique over an 8-ye

253 , whereas clade 2 was associated with penile-vaginal sex and sharing of sex toys with female partners

254 at comparably large reductions in penile and vaginal SHIV infection risk among macaques were achieved

255 ited significant protection against repeated vaginal SHIV(AD8-EO) exposures.

256 Finally, PCRs of nanH2 or nanH3 from human vaginal specimens had 81% sensitivity and 78% specificit

257 Longitudinal self-collected vaginal specimens were analyzed using established G. vag

258 Women were randomly assigned to receive vaginal suppositories containing either 400 mg of proges

259 obtained from testing either self-collected vaginal swab or clinician-collected male urethral swab s

260 tive was to measure cytology and proteome of vaginal swab samples taken on postnatal day (PND) 2 and

261 ly detect: i) HPV DNA in saliva and clinical vaginal swab samples, and ii) HIV RNA in plasma samples

262 sed with sham-infected males had no positive vaginal swab specimen cultures or C. muridarum-positive

263 to 99.9%) for clinician- and self-collected vaginal swab specimens, respectively; 93.3% (95% CI, 89.

264 ormance of the AMG assay by testing residual vaginal swab, female urine, and male urine specimens obt

265 Patient- and clinician-collected vaginal-swab samples obtained from women with symptoms o

266 The sensitivities in female vaginal swabs and urine samples were 96.6% (95% confiden

267 Shotgun sequencing of vaginal swabs from postmenopausal women self-identified

268 Consequently, VOC analysis of vaginal swabs has potential to be used as a predictive t

269 Live C. trachomatis recovered from vaginal swabs or endometrial tissues peaked on day 3 and

270 Using vaginal swabs taken closest to delivery, VOC analysis is

271 Proteins isolated from vaginal swabs taken on PND 2 and 16 from six gilts acros

272 Abundance of Lactobacillus in vaginal swabs was correlated with 3TC-TP concentrations

273 ECs in vaginal swabs were analyzed with cytofluorimetric analys

274 Vaginal swabs were collected from 93 women (mean age, 23

275 hort study demonstrates that VOC analysis of vaginal swabs, taken in the midtrimester, is a fair test

276 We aimed to ascertain if VOC analysis of vaginal swabs, taken throughout pregnancy, could predict

277 quencing was performed on DNA extracted from vaginal swabs.

278 e Bifidobacterium species), or Gynophilus LP vaginal tablet (L. rhamnosus 35) for two months.

279 ssociated with HSV-2 in female partners, and vaginal taxa are associated with HSV-2 in male partners.

280 trations of 5P12-RANTES in vaginal fluid and vaginal tissue between 10 and 10,000 ng/g over 28days, a

281 Antigen stimulation of T cells in ex vivo vaginal tissue cultures triggered antiviral responses in

282 als including asphalt concrete, agarose gel, vaginal tissue, polymer, agar, bone, spider silk, and hy

283 M) cells that infiltrate healed sites of the vaginal tissues.

284 faecalis colonization and persistence in the vaginal tract.

285 t and -sensitive strains colonize the murine vaginal tract.

286 ncentrations of RPV were required to inhibit vaginal transmission of HIV-1 with little or no resistan

287 evaluated the efficacy of RPV LA to inhibit vaginal transmission of RPV-resistant HIV-1 in humanized

288 RPV LA significantly prevented vaginal transmission of WT HIV-1 and Y181C HIV-1, which

289 manized mice, we found that RPV LA inhibited vaginal transmission of WT or 3-fold RPV-resistant HIV-1

290 in the systemic circulation, as well as the vaginal vault and intestinal lumen, with CCL20 playing a

291 mates associations between mode of delivery (vaginal vs cesarean delivery) and maternal and neonatal

292 hibitor, improved recovery of the parturient vaginal wall after obstetrical injury.

293 ed to minimize disruption to the undeveloped vaginal wall and postoperative pain while providing exce

294 Stiffness of the vaginal wall decreased 82% in pregnant rats and 74% (p =

295 ficant deleterious impact on recovery of the vaginal wall from pregnancy.

296 rs, biomechanics, and histomorphology of the vaginal wall in rats.

297 ease inhibitor, on obstetrical injury of the vaginal wall.

298 act on vaginal FBLN5 and biomechanics of the vaginal wall.

299 However, IgA was found only in the vaginal washes and fecal extracts of p.o.-immunized anim

300 Blood and vaginal washes were collected for host immunologic respo